Deal-happy Sanofi to buy cancer-drug developer

In its second half-billion-dollar deal in a week, Sanofi-Aventis has agreed to buy the U.S. cancer drug specialist BiPar Sciences, aiming to build up its presence in biotech oncology meds. Report

Suggested Articles

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.

After Merck and Bayer's vericiguat scored in a heart failure trial, you'd expect potential rivals to brace themselves. Not so for Novartis'…